Viking Therapeutics (NASDAQ:VKTX) Stock Rating Upgraded by Zacks Research
Zacks Research has upgraded Viking Therapeutics (NASDAQ:VKTX) from a "strong sell" to a "hold" rating. This upgrade follows varied analyst opinions, with the stock currently holding a "Moderate Buy" consensus rating and an average price target of $87.80. Recent financial data shows the company missed its last quarterly earnings estimate, and several insiders have sold shares.
Can Viking Therapeutics Really Soar 300%? Why Wall Street Is Betting Big on This Biotech Stock
Wall Street analysts are bullish on Viking Therapeutics (VKTX), with some predicting over 300% upside, largely driven by its lead weight-loss drug candidate, VK2735. This drug, a GLP-1 receptor agonist, is in Phase 3 trials and potentially offers a competitive edge in tolerability and convenience (oral version in development). Despite intense competition in the massive GLP-1 market, analysts believe capturing even a small share could significantly boost Viking's stock, and the company is also developing new pipeline candidates beyond VK2735.
Looking Into Viking Therapeutics Inc's Recent Short Interest
Viking Therapeutics Inc. (NYSE: VKTX) has seen a 3.72% increase in its short interest, with 26.06 million shares now sold short, representing 27.63% of available shares. This higher-than-peer short interest may signal increased bearish sentiment, taking traders 9.88 days on average to cover their positions. Short interest is an important indicator of market sentiment, and while rising short interest doesn't guarantee a stock will fall, it indicates that more shares are being shorted compared to its peers.
Viking Therapeutics Expands Obesity Pipeline As VK2735 Nears Late Stage Trials
Viking Therapeutics is significantly expanding its obesity drug pipeline as its injectable VK2735 nears late-stage trials and an oral version moves towards Phase 3. The company also plans to file an IND for a new amylin agonist. While Viking (NasdaqCM:VKTX) is currently operating at a net loss, its multi-asset approach in a large market dominated by Eli Lilly and Novo Nordisk could offer diverse treatment options, making future clinical readouts and regulatory milestones critical for investors.
Viking Therapeutics, Inc. (VKTX) Stock Analysis: Evaluating a 219.73% Potential Upside in Biotech Innovation
Viking Therapeutics (VKTX) is a clinical-stage biotechnology company with a robust pipeline of drug candidates targeting metabolic and endocrine disorders, including lead candidate VK2809 for NASH and NAFLD. Despite current unprofitability and negative financial metrics common for early-stage biotechs, analysts are overwhelmingly positive, with a potential upside of 219.73% and an average target price of $92.72, signaling significant growth potential for high-risk tolerant investors.
Responsive Playbooks and the VKTX Inflection
This article analyzes Viking Therapeutics Inc. (NASDAQ: VKTX) using AI models, identifying a positive near-term sentiment but a weak mid-term bias within a long-term strength context. It offers three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strengths, support, and resistance levels for VKTX.
Viking Therapeutics Builds Obesity Platform As VK2735 Trials Accelerate
Viking Therapeutics is rapidly advancing its lead obesity therapy, VK2735, through Phase 3 trials for both subcutaneous and planned oral formulations, and is preparing to file an IND for a new amylin agonist. Recent manufacturing agreements and leadership appointments indicate the company is preparing for potential commercialization as it expands its product pipeline and go-to-market strategies. While showing high potential in a competitive market, Viking recorded a significant net loss in 2025, highlighting the high-risk, high-reward nature of this biotech investment, contingent on successful trial outcomes and future partnerships.
Viking Therapeutics Builds Obesity Platform As VK2735 Trials Accelerate
Viking Therapeutics is rapidly advancing its lead obesity therapy, VK2735, through Phase 3 trials for both injectable and planned oral formulations, aiming to build a broad obesity platform. The company is also preparing an IND filing for a new amylin agonist candidate and has appointed a Chief Commercial Officer and signed a manufacturing agreement, indicating a strategic shift towards commercialization readiness. Despite a significant 2025 net loss, these developments frame Viking as a high-risk, high-potential biotech focusing on multiple pathways to market in the competitive obesity drug landscape.
Viking Therapeutics (VKTX) Rebounds on Bargain-Hunting. Are You Missing Out?
The article discusses Viking Therapeutics (VKTX) stock, noting its recent rebound suggests potential bargain-hunting. It encourages readers to evaluate if they are missing out on this opportunity, particularly given a significant 202% price increase over the last four weeks. The text then prompts users to visit the MSN financial page for VKTX for further information.
What is HC Wainwright's Forecast for VKTX Q4 Earnings?
HC Wainwright analyst J. Pantginis forecasts Viking Therapeutics (VKTX) Q4 EPS to be ($0.81), with the full-year loss estimated at ($1.56). Despite missing the Q4 consensus by ($0.49), the stock received a boost from positive pipeline developments, including a planned Phase 3 start for oral VK2735 and a strong cash balance of approximately $706 million. The company's stock currently holds an average rating of "Moderate Buy" with an average price target of $87.80.
Viking Therapeutics Stock Forecast 2026–2030 | Future Outlook
This article provides an outlook on Viking Therapeutics (VKTX) stock, including third-party price targets and technical analysis for 2026-2030. It highlights the company's metabolic pipeline, particularly its obesity and liver-disease drug candidates, as key drivers for future performance. The stock's past volatility and sensitivity to clinical trial results and market sentiment are also discussed.
Viking Therapeutics stock rating reiterated at Buy by Laidlaw
Laidlaw has reiterated a Buy rating on Viking Therapeutics (NASDAQ:VKTX) with a price target of $110.00, citing the company's clear pathways for advancing its VK2735 obesity treatment program. Despite a recent earnings miss in Q4 2025, Viking's strong financial position and plans for Phase III studies of its oral formulation in 2026 support the positive outlook. Analyst targets for VKTX range from $36 to $125, with a broader consensus of "Strong Buy."
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript
Viking Therapeutics reported its Q4 and full-year 2025 financial results, highlighting significant progress in its obesity pipeline with VK2735. The company initiated Phase III trials for its subcutaneous VK2735 formulation and plans to advance the oral formulation into Phase III in Q3 2026. Viking also discussed a maintenance dosing study for VK2735, its amylin agonist program, and manufacturing agreements, while confirming sufficient cash reserves for upcoming milestones.
Viking Therapeutics, Inc. SEC 10-K Report
Viking Therapeutics, Inc. has released its annual 10-K report, detailing its financial performance, operations, and strategic initiatives. The clinical-stage biopharmaceutical company reported no revenue but significant R&D expenses as it advances drug candidates like VK2735 and VK2809. The report also highlights future outlook, including planned Phase 3 studies and capital management strategies, alongside operational, regulatory, and market risks.
Viking Therapeutics plans to advance oral obesity drug to late-stage testing
Viking Therapeutics announced plans to move its experimental oral obesity drug, VK2735, into late-stage trials in the third quarter of this year, causing its shares to rise. The company believes its dual oral and injectable formulations using the same active ingredient will differentiate it from rivals, and its CEO noted promising initial uptake for other oral obesity peptides. Viking holds $706 million in cash, which it states is sufficient to complete these trials and pursue further development.
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline
Viking Therapeutics (VKTX) stock rose 9% after announcing plans to advance its oral experimental obesity drug VK2735 into late-stage trials by Q3 2026, while its subcutaneous formulation is already in late-stage development. The company also intends to file an application for trials of a new amylin agonist this quarter to broaden its portfolio. Despite reporting a wider-than-expected loss in Q4 2025 due to increased R&D, retail sentiment on Stocktwits remained bullish for VKTX.
Earnings call transcript: Viking Therapeutics Q4 2025 misses EPS forecast
Viking Therapeutics reported a significant miss in its Q4 2025 earnings per share, coming in at -$1.38 against a forecast of -$0.9, a 53.33% negative surprise. Despite this, the company's stock saw a slight increase in aftermarket trading, reflecting investor confidence in its strategic advancements, particularly in the obesity treatment market with its VK2735 program. The company is progressing with both subcutaneous and oral formulations of VK2735, with phase 3 trials
Viking Therapeutics (NASDAQ:VKTX) Announces Earnings Results
Viking Therapeutics (NASDAQ:VKTX) reported Q4 earnings per share of ($1.38), missing the consensus estimate of ($0.89), causing its stock to trade down approximately 0.7%. Insider selling by CEO Brian Lian and CFO Greg Zante was notable, with a total of 364,731 shares worth $12.05M sold in the quarter. Despite mixed analyst ratings, the company holds a "Moderate Buy" consensus with a high average price target of $89.36.
Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
Viking Therapeutics announced its Q4 and year-end 2025 financial results, highlighting significant progress in its obesity portfolio. Key updates include the advancement of oral VK2735 into Phase 3 for obesity, ongoing Phase 3 VANQUISH trials for subcutaneous VK2735 nearing full enrollment, and completion of enrollment for a maintenance dosing study with data expected in Q3 2026. The company also reported a strong cash position of $706 million at year-end and plans to file an IND for a novel amylin agonist this quarter.
Principal Financial Group Inc. Trims Holdings in Viking Therapeutics, Inc. $VKTX
Principal Financial Group Inc. reduced its stake in Viking Therapeutics (NASDAQ:VKTX) by 9.0% in Q3, selling 51,064 shares and retaining 514,002 shares valued at approximately $13.51 million. Insider selling has also been reported, with the CEO and other insiders selling a total of 364,731 shares in the last quarter. Despite this, institutional ownership is high at 76.03%, and Wall Street analysts maintain a "Moderate Buy" rating with an average target price significantly above the current share price.
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by Brokerages
Viking Therapeutics, Inc. (NASDAQ:VKTX) has received an average rating of "Moderate Buy" from fourteen brokerages, with an average one-year price target of $89.36. The clinical-stage biopharmaceutical company's stock opened at $28.75, and its market capitalization stands at $3.25 billion. Insider selling, including significant sales by the COO and CFO, has been noted, while institutional investors hold approximately 76% of the company's stock.
Viking Therapeutics, Inc. $VKTX Shares Bought by RFG Advisory LLC
RFG Advisory LLC recently increased its stake in Viking Therapeutics (NASDAQ:VKTX) by 84.8%, now owning 120,214 shares valued at $3.16 million. Other institutional investors like Norges Bank and Cubist Systematic Strategies LLC also significantly increased their holdings. Despite notable insider selling by COO Marianna Mancini and CFO Greg Zante, institutional ownership stands at approximately 76.03%, with analysts giving VKTX a "Moderate Buy" rating and a consensus price target of $89.36.
Understanding the Setup: (VKTX) and Scalable Risk
This article analyzes Viking Therapeutics Inc. (VKTX) using AI-generated signals, highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents three trading strategies for different risk profiles: Position Trading, Momentum Breakout, and Risk Hedging, along with support and resistance levels across various time horizons.
Commit To Buy Viking Therapeutics At $17.50, Earn 22.9% Using Options
This article suggests that investors interested in Viking Therapeutics Inc (VKTX) but cautious about its current market price can consider selling a put option. Specifically, it highlights the December 2027 put at a $17.50 strike price, which offers a 22.9% return (12.3% annualized) on the commitment, provided the shares do not drop significantly below the strike price. This strategy allows investors to collect a premium while potentially acquiring shares at a lower cost basis if the option is exercised.
Viking Therapeutics (VKTX) Is Considered a Good Investment by Brokers: Is That True?
The article "Viking Therapeutics (VKTX) Is Considered a Good Investment by Brokers: Is That True?" appears to be missing its main content, as it only contains the title, publication time, and the source "MSN." Without the full article text, it's impossible to determine why brokers might consider Viking Therapeutics a good investment or to evaluate the claims made in the title.
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
Viking Therapeutics (NASDAQ: VKTX) will release its financial results for the fourth quarter and full-year 2025 after market close on Wednesday, February 11, 2026. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss these results and provide corporate updates. A replay of the call will be available until February 18, 2026, and a webcast archive will be accessible on its website for 30 days.
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
Viking Therapeutics announced it will release its financial results for the fourth quarter and year-end 2025 after the market closes on Wednesday, February 11, 2026. The company will also host a conference call on the same day at 4:30 p.m. Eastern Time to discuss these results and provide general corporate updates. A replay of the call will be available until February 18, 2026, and a webcast archive will be accessible for 30 days on Viking's website.
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
Viking Therapeutics will announce its financial results for the fourth quarter and year-end 2025 after market close on Wednesday, February 11, 2026. The company will also host a conference call on the same day at 4:30 p.m. Eastern Time to discuss these results and provide general corporate updates. Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders.
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
Viking Therapeutics announced it will release its financial results for the fourth quarter and year-end 2025 after market close on Wednesday, February 11, 2026. The company will host a conference call on the same day at 4:30 p.m. Eastern Time to discuss the results and provide general corporate updates. Instructions for participating in the call and accessing the webcast replay were provided.
Viking Therapeutics Shares Face Sector-Wide Pressure
Viking Therapeutics' shares are under pressure due to a sector-wide downturn triggered by Novo Nordisk's disappointing 2026 outlook. Investors are now focusing on Viking's upcoming Q4 and full-year 2025 results and management commentary, particularly regarding the VK2735 injectable program’s Phase 3 VANQUISH data timeline and oral formulation strategy, as it seeks to differentiate itself in the competitive obesity treatment market. The company’s ability to provide clear clinical milestones will be crucial for its valuation.
Assessing Viking Therapeutics (VKTX) After Recent Share Price Declines and DCF Valuation Estimate
This article assesses Viking Therapeutics (VKTX) following recent share price declines, using two valuation approaches. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 89.2%, estimating intrinsic value at $273.00 per share. However, a Price-to-Book (P/B) ratio analysis indicates the stock is overvalued when compared to its proprietary Fair Ratio, despite trading below some peer averages.
VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report
Viking Therapeutics (VKTX) stock saw significantly increased retail investor attention ahead of its Q4 earnings report, with message volume tripling on Stocktwits and sentiment shifting to bullish. The company is expected to report a loss per share of $0.91, and its lead candidate VK2735 for obesity is in late-stage trials, sparking acquisition speculations among retail traders. CEO Brian Lian has indicated openness to partnerships for the obesity program.
The Smartest Growth Stock to Buy With $30 Right Now
Viking Therapeutics (NASDAQ: VKTX) is presented as a high-potential growth stock in the expanding obesity drug market, estimated to reach $150 billion by 2035. While the company is still in the development phase for its VK2735 drug, clinical trials have shown promise, and its relatively small market cap of $3.3 billion offers significant upside if the drug gains regulatory approval. Investors are encouraged to consider it as a speculative but potentially rewarding addition to a diversified portfolio.
Viking Therapeutics to report Q4 earnings: Here's what to know
This article announces that Viking Therapeutics is scheduled to report its Q4 earnings. It highlights that investors will be keen to learn about the company's financial performance and future outlook.
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market
Viking Therapeutics, Inc. (VKTX) stock closed down 3.9% at $29.06, underperforming the broader market. The company also lagged the Medical sector over the past month, with its stock declining 14.04%. Analysts forecast a significant year-over-year decrease in EPS for its upcoming earnings, and the stock currently holds a Zacks Rank #4 (Sell).
Viking Therapeutics to Report Q4 Earnings: Here's What to Know
Viking Therapeutics is expected to report its Q4 and full-year 2025 earnings next month, with investor focus on the progress of its lead obesity drug candidate, VK2735. The company is studying both oral and subcutaneous formulations of VK2735 in late-stage trials and completed enrollment for the VANQUISH-1 study in November 2025. Despite promising early results from its NASH and X-ALD programs, the company faces significant competition in the obesity market and has a history of missing earnings estimates.
Viking Therapeutics (VKTX) to Release Quarterly Earnings on Wednesday
Viking Therapeutics (VKTX) is set to announce its Q4 2025 earnings before market open on Wednesday, February 4th, with analysts forecasting a loss of ($0.89) per share. The announcement follows significant insider selling on January 5th by the CFO and CEO, totaling over $9.5 million. Despite this, the stock carries a "Moderate Buy" consensus rating with a target price of $87.14, and institutional investors have recently increased their holdings.
Assessing Viking Therapeutics (VKTX) After Recent Pullback And Ongoing Pipeline Headlines
This article analyzes Viking Therapeutics (VKTX) after a recent share price pullback, examining its valuation using Discounted Cash Flow (DCF) analysis and Price-to-Book (P/B) ratio. The DCF model suggests the stock is significantly undervalued, while the P/B ratio indicates it's about right compared to its peers. The article also introduces "Narratives" as a way for investors to build customized valuation models based on their own forecasts.
Viking Therapeutics, Inc. (VKTX) Advances Obesity Drug Development and Expands Metabolic Disease Pipeline
Viking Therapeutics, Inc. (VKTX) announced a significant milestone in the development of its obesity drug VK2735, which achieved 14.7% weight loss in a Phase 2 trial. The company is now evaluating the drug in a Phase 3 trial and aims to tap into the potential $150 billion obesity drug market. Viking Therapeutics is also developing drugs for other metabolic and endocrine diseases.
Viking Therapeutics, Inc. (VKTX) Advances Obesity Drug Development and Expands Metabolic Disease Pipeline
Viking Therapeutics, Inc. (VKTX) is making significant strides in obesity drug development with its drug VK2735, which achieved 14.7% weight loss in a Phase 2 trial and is now in Phase 3. The company, a clinical-stage biopharma firm, is also developing drugs for other metabolic and endocrine diseases. The article notes the potential growth of VKTX but suggests that some AI stocks might offer even higher returns with less downside risk.
Viking Therapeutics (VKTX) Is Down 5.0% After Phase 2 VK2735 Data And Phase 3 Updates – Has The Bull Case Changed?
Viking Therapeutics (VKTX) recently published positive Phase 2 VENTURE trial data for its dual GLP-1/GIP agonist VK2735, showing significant weight loss and a mild side-effect profile, and confirmed full enrollment for Phase 3 trials. Despite these positive developments, the company's shares are down, and its valuation remains high with no current revenue, indicating high execution risk for VK2735's clinical and commercial success. The investment narrative largely depends on VK2735, with analysts having widely divergent fair value estimates for the stock.
Viking Therapeutics (VKTX) Is Down 5.0% After Phase 2 VK2735 Data And Phase 3 Updates – Has The Bull Case Changed?
Viking Therapeutics (VKTX) shares dropped 5.0% after the announcement of positive Phase 2 VK2735 data for obesity and updates on its ongoing Phase 3 trials and a maintenance dosing study. The article discusses how these developments may affect the company's investment outlook, highlighting that while the data strengthens confidence in VK2735 as a key catalyst, Viking Therapeutics still faces risks due to zero revenue, rising losses, and a valuation that already presumes significant future success. Despite the retreat in stock price, valuation concerns persist, with fair value estimates for VKTX varying widely.
Viking Therapeutics (NASDAQ:VKTX) Downgraded by Zacks Research to Strong Sell
Viking Therapeutics (NASDAQ:VKTX) has been downgraded by Zacks Research from a "hold" to a "strong sell" rating. This downgrade comes despite an overall mixed-to-positive analyst consensus of "Moderate Buy" and an average price target of $87.14. The report also highlighted significant insider selling, with over $15 million worth of shares disposed of by insiders in the last quarter, and the company missing its Q3 EPS consensus estimate.
Assessing Viking Therapeutics (VKTX) Valuation After VK2735 Phase 2 Success And Phase 3 Trial Progress
Viking Therapeutics (VKTX) is being re-evaluated following successful Phase 2 results for VK2735 and full enrollment in two Phase 3 trials for obesity and diabetes. While the company's price-to-book ratio suggests it is overvalued compared to its peers, a discounted cash flow (DCF) model indicates significant undervaluation, trading roughly 87.9% below an implied fair value of around US$276.53 per share. This discrepancy highlights the market's challenge in valuing a clinical-stage biopharma company with high future potential but current net losses.
Can Viking Therapeutics Make a Turnaround This Year?
Viking Therapeutics faces a challenging year with its stock lagging behind the S&P 500 despite optimistic analyst targets. The company's future hinges on the clinical trial results of its core drug candidate, VK2735, for weight management, particularly the Phase III data expected in 2027 and an ongoing maintenance therapy study. While short-term gains are uncertain, the article suggests long-term potential due to the growing weight-loss market and VK2735's promising mid-stage results.
Viking Therapeutics (VKTX) Faces Challenges, Analysts Set Price Target of $93.39, Potential Upside of 175%
Viking Therapeutics (VKTX) is experiencing poor stock performance due to slow clinical progress, with shares lagging the S&P 500. Despite these challenges, analysts have set an average price target of $93.39, projecting a potential upside of 175% based on confidence in future products and upcoming critical trials for its leading candidate, VK2735. The company is actively developing a diversified pipeline, including a maintenance study for VK2735 and other therapies for metabolic and endocrine disorders.
2 Bargain Stocks You Can Buy for Less Than $100 Right Now
The article highlights two bargain stocks, Viking Therapeutics (VKTX) and PayPal (PYPL), that are currently trading for less than $100 and are considered underrated buys with promising growth prospects. Viking Therapeutics, despite having no approved products, shows high potential with its GLP-1 weight loss drug, VK2735, currently in phase 3 trials. PayPal, a more established fintech company, is working to boost its growth rate and market position through strategic partnerships and expanding its Venmo app for everyday purchases, despite recent growth challenges.
Viking Therapeutics' Price Target of $93.39 Implies 175% Upside Potential
Despite recent poor stock performance and slow clinical progress for Viking Therapeutics (VKTX), analysts have set an average price target of $93.39, suggesting a 175% upside. This optimism is driven by the potential of its lead drug candidate, VK2735, currently in a 78-week Phase 3 study with results anticipated in 2027, as well as ongoing diversification of its pipeline. Several analysts have issued "Buy" or "Overweight" ratings, citing strong efficacy data and swift execution across programs.
What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026?
Viking Therapeutics experienced significant stock volatility in 2025 due to clinical trial results for its lead drug candidate, VK2735, a dual GLP-1/GIP agonist for diabetes and obesity. While the oral form of VK2735 faced safety concerns leading to a 20% discontinuation rate in its Phase 2 trial, its efficacy was promising, and the company's subcutaneous form also shows potential. Given the high interest in obesity drugs, Viking's strong cash position, and ongoing trials, it remains a potential acquisition target for larger pharmaceutical companies in 2026.
Why Viking Therapeutics (VKTX) Is Up 6.1% After VK2735 Phase 2 Obesity Data And Phase 3 Progress
Viking Therapeutics (VKTX) saw its stock rise by 6.1% following positive peer-reviewed Phase 2 data for its obesity drug VK2735, which showed significant weight loss. The company is now progressing into Phase 3 trials (VANQUISH-1 and VANQUISH-2), with enrollment largely completed, aiming to evaluate longer-term efficacy and safety for both obesity and type 2 diabetes. While the promising data and ongoing Phase 3 trials strengthen the investment narrative, risks include high cash burn, intense competition in the GLP-1/GIP space, and the need for successful Phase 3 outcomes and regulatory approval.
